Meige's disease, or osteomalaxia, is a metabolic disorder in bone tissue that causes it to become soft and fragile. This disorder is caused by a deficiency of vitamin D, which plays a key role in the absorption of calcium and phosphorus, which are essential for maintaining healthy bones. The clinical picture of the disease includes a variety of symptoms, such as bone pain, muscle weakness, skeletal deformities, and an increased risk of fractures. Osteomalaxia can be primary, resulting from a deficiency of vitamin D, or secondary, associated with metabolic disorders or diseases of the kidneys, liver, and intestines that affect the metabolism of vitamin D and minerals.
History of the disease and interesting historical facts
Meige's disease was first described in the early 19th century. In 1824, the English physician A. Meige published his observations of patients with characteristic signs of osteomalacia. Since the disease was often observed in women during pregnancy and lactation, this gave rise to further research related to vitamin D deficiency and its impact on bone health. Later, with the development of medicine and science, a connection was established between sunlight, vitamin D and bone health. It was the study of sunlight as a source of vitamin D that formed the basis of modern recommendations for the prevention of osteomalacia and other diseases associated with impaired calcium and phosphorus metabolism.
Epidemiology
The epidemiology of Meige's disease shows significant regional variations. Statistically, osteomalacia is more often recorded in areas with low levels of solar activity, which leads to insufficient formation of vitamin D in the skin. About 25% of the population in northern regions of the world has low levels of vitamin D. At risk are the elderly, people with limited mobility and those who spend very little time in the sun. According to the World Health Organization, the disease affects about 1-3% of the population globally, with a high incidence among certain groups such as postmenopausal women.
Genetic predisposition to this disease
Genetic factors play an important role in predisposition to Meige's disease. Research suggests that certain mutations in genes involved in vitamin D metabolism may increase the risk of developing osteomalacia. In particular, mutated versions of the VDR (vitamin D receptor) and CYP27B1 (a gene encoding an enzyme involved in activating vitamin D) genes have been associated with an increased predisposition to the disease. It is also important to note that genetic polymorphisms may affect vitamin D levels in the body, calcium and phosphorus absorption, which in turn may contribute to the development of the disease.
Risk factors for the development of this disease
Risk factors for osteomalacia can be divided into several categories, including:
- Physical factors: limitations in physical activity, lack of sunlight, low level of external influence on the body.
- Chemical factors: Exposure to toxic substances, such as certain heavy metals, can reduce vitamin D levels.
- Other factors: Chronic diseases such as Crohn's disease and celiac disease, which can affect the absorption of vitamin D and minerals in the intestine.
Diagnosis of this disease
Diagnosis of Meige's disease is based on clinical manifestations and laboratory tests. The main symptoms include:
- Pain in bones and joints.
- Muscle weakness.
- Skeletal deformities such as kyphosis or osteoporosis.
Laboratory tests show serum calcium, phosphorus, and vitamin D levels to assess metabolism. Radiological examinations such as X-rays and MRIs may reveal typical changes in bone tissue, such as softening and increased fragility. Other diagnostics include bone biopsy to confirm the diagnosis. Differential diagnosis should include osteoporosis and other diseases that affect bone metabolism.
Treatment
Treatment for osteomalacia involves several main approaches. General treatment is aimed at correcting vitamin D, calcium, and phosphorus levels in the body. Pharmacological treatment often involves vitamin D supplements such as cholecalciferol or ergocalciferol. In severe cases, surgery may be required to correct bone deformities. Other therapies may include physical therapy to improve muscle tone and increase physical activity, which is also important for restoring bone health.
List of medications used to treat this disease
The following drugs are used in the treatment of Meige's disease:
- Cholecalciferol (vitamin D3).
- Eurgocalciferol (vitamin D2).
- Calcitriol (active form of vitamin D).
- Calcium phosphate as a source of calcium.
- Other vitamin complex supplements with essential minerals.
Disease monitoring
Monitoring a patient with Meige's disease includes checkpoints, assessment of vitamin D and other mineral levels in the blood, and regular X-rays to detect possible changes in bone tissue. The prognosis depends on the severity of the disease and compliance with the doctor's recommendations. Complications may include fractures, chronic pain, and structural changes in the bones.
Age-related features of the disease
The course of Meige's disease varies depending on the age group. In children, the disease may manifest itself through growth and developmental disorders, while in older people, more pronounced symptoms are observed, such as slower recovery from injuries and increased bone fragility. Osteomaxillary osteomalacia is more common in women during menopause due to changes in hormonal levels, which also exacerbates problems with the absorption of vitamin D.
Questions and Answers
- What is Meige's disease? Meige's disease, or osteomalaxia, is a condition associated with softening of bone tissue due to a lack of vitamin D.
- What causes osteomalacia? The main cause is a lack of vitamin D, which leads to impaired absorption of calcium and phosphorus.
- How is Meige's disease diagnosed? Diagnosis includes testing for vitamin D levels in the blood and radiological assessment of bone condition.
- Can osteomalacia be cured? Yes, osteomalacia can be treated by correcting the levels of vitamin D and minerals in the body.
- Who is at risk for developing Meige's disease? Those at risk include the elderly, people with limited mobility and patients with diseases that affect the absorption of vitamins.
